ITRM vs PATH
Iterum Therapeutics PLC (ITRM) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Iterum Therapeutics PLC (ITRM) is a biotechnology company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported ITRM revenue for 2025-09-30 was $390.0K. Net income was -$20.4M. ITRM currently screens at market cap $38.6M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
ITRM currently screens at market cap $38.6M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the ITRM and PATH stock pages for the full models.
Not investment advice.